HERCLON 440MG ING

About

Trastuzumab (Herclon) is a monoclonal antibody specifically designed to target the human epidermal growth factor receptor 2 (HER2) protein, which is overexpressed in certain aggressive types of cancer cells, particularly in breast and gastric cancers. By binding to the HER2 receptor on the surface of these malignant cells, Herclon effectively inhibits their growth and proliferation, thereby slowing or stopping tumor progression. This targeted therapy represents a significant advancement in oncology, offering a more precise approach to treatment by directly attacking cancer cells while sparing healthy tissues. Its mechanism of action involves not only the direct inhibition of cell signaling pathways crucial for cancer cell survival but also the recruitment of immune cells to destroy HER2-positive cancer cells, leading to improved clinical outcomes for patients with HER2-positive malignancies.

Uses

• HER2-positive metastatic breast cancer
• Adjuvant treatment of HER2-positive early breast cancer
• HER2-positive metastatic gastric cancer
• HER2-positive gastroesophageal junction adenocarcinoma

Directions For Use

Administered intravenously by a healthcare professional, typically as an infusion over a specified period.

Benefits

• Significantly improves survival rates in HER2-positive cancers
• Reduces the risk of disease recurrence
• Offers targeted therapy with less harm to healthy cells
• Effective in combination with chemotherapy
• Well-established efficacy in various HER2-positive malignancies
• Can improve quality of life for patients

Side Effects

• Cardiotoxicity (e.g., heart failure)
• Infusion-related reactions (fever, chills)
• Nausea
• Diarrhea
• Headache
• Rash
• Fatigue
• Neutropenia (low white blood cell count)
• Anemia
• Peripheral neuropathy
• Interstitial lung disease (rare)
• Hypersensitivity reactions

Safety Measures

• Alcohol - No direct interaction, but alcohol consumption should be discussed with a doctor during cancer treatment due to potential for exacerbating side effects or general health impact.
• Pregnancy - Contraindicated due to potential for severe fetal harm, including oligohydramnios and renal dysfunction. Effective contraception is required during and for 7 months after treatment.
• Breastfeeding - Not recommended due to potential for serious adverse reactions in breastfed infants. Discontinue breastfeeding during treatment and for 7 months after the last dose.
• Liver - Use with caution in patients with pre-existing liver conditions; monitor liver function tests regularly during treatment.
• Kidney - Use with caution in patients with renal impairment; monitor renal function closely as dose adjustments may be considered in severe cases.
• Lung - Use with caution in patients with pre-existing pulmonary conditions due to the risk of interstitial lung disease and other pulmonary toxicities.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.